254 related articles for article (PubMed ID: 37240077)
1. Epigenetic Alterations in DCIS Progression: What Can lncRNAs Teach Us?
Petrone I; Santos ECD; Binato R; Abdelhay E
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240077
[TBL] [Abstract][Full Text] [Related]
2. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
3. Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer.
DeVaux RS; Herschkowitz JI
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):223-235. PubMed ID: 30306389
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling.
DeVaux RS; Ropri AS; Grimm SL; Hall PA; Herrera EO; Chittur SV; Smith WP; Coarfa C; Behbod F; Herschkowitz JI
J Cell Biochem; 2020 Jul; 121(7):3465-3478. PubMed ID: 31907974
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of an epigenetically regulated long noncoding RNA model for breast cancer metabolism and prognosis.
Song Y; Shen S; Sun Q
BMC Med Genomics; 2022 May; 15(1):105. PubMed ID: 35525949
[TBL] [Abstract][Full Text] [Related]
8. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
9. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation in ductal carcinoma in situ of the breast.
Pang JM; Dobrovic A; Fox SB
Breast Cancer Res; 2013 Jun; 15(3):206. PubMed ID: 23826974
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology.
Zhang Z; Weaver DL; Olsen D; deKay J; Peng Z; Ashikaga T; Evans MF
J Clin Pathol; 2016 Jan; 69(1):76-81. PubMed ID: 26323944
[TBL] [Abstract][Full Text] [Related]
13. miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2018 Mar; 188(3):542-549. PubMed ID: 29246496
[TBL] [Abstract][Full Text] [Related]
14. Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
Cowell CF; Weigelt B; Sakr RA; Ng CK; Hicks J; King TA; Reis-Filho JS
Mol Oncol; 2013 Oct; 7(5):859-69. PubMed ID: 23890733
[TBL] [Abstract][Full Text] [Related]
15. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
17. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.
Fleischer T; Frigessi A; Johnson KC; Edvardsen H; Touleimat N; Klajic J; Riis ML; Haakensen VD; Wärnberg F; Naume B; Helland A; Børresen-Dale AL; Tost J; Christensen BC; Kristensen VN
Genome Biol; 2014; 15(8):435. PubMed ID: 25146004
[TBL] [Abstract][Full Text] [Related]
19. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.
Zikan M; Bohm J; Pavlista D; Cibula D
Clin Transl Oncol; 2011 Sep; 13(9):652-5. PubMed ID: 21865136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
